Funding for this research was provided by:
Credo
Article History
Received: 3 April 2024
Accepted: 4 July 2024
First Online: 13 July 2024
Competing interests
: Outside of this work, ZDC reports receiving study drug from Canopy Growth Corp and True Terpenes, and study-related materials from Storz & Bickel. She served a scientific consultant for Canopy Growth Corporation in 2021 and on the scientific advisory board for FSD Pharma in 2020. ZDC’s research is funded by grants from the National Institute on Drug Abuse, National Center for Complementary and Integrative Health, California Department of Cannabis Control, Center for Medicinal Cannabis Research, and the California Highway Patrol. ER is founder and CEO of CReDO science which formulates and works with CBG. ZDC and ER had no role in the analyses or interpretation of the findings. Dr. Cuttler reports receiving study-related materials from Storz & Bickel as well as research funds from Huxley Health and Healer. Amanda Stueber declares no conflicts of interest.